181 related articles for article (PubMed ID: 26271057)
1. Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial.
Bittner V; Bertolet M; Barraza Felix R; Farkouh ME; Goldberg S; Ramanathan KB; Redmon JB; Sperling L; Rutter MK;
J Am Coll Cardiol; 2015 Aug; 66(7):765-773. PubMed ID: 26271057
[TBL] [Abstract][Full Text] [Related]
2. Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes).
Tamis-Holland JE; Lu J; Korytkowski M; Magee M; Rogers WJ; Lopes N; Mighton L; Jacobs AK;
J Am Coll Cardiol; 2013 Apr; 61(17):1767-76. PubMed ID: 23500245
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial.
Dagenais GR; Lu J; Faxon DP; Bogaty P; Adler D; Fuentes F; Escobedo J; Krishnaswami A; Slater J; Frye RL;
J Am Coll Cardiol; 2013 Feb; 61(7):702-11. PubMed ID: 23410541
[TBL] [Abstract][Full Text] [Related]
4. Increased Hazard of Myocardial Infarction With Insulin-Provision Therapy in Actively Smoking Patients With Diabetes Mellitus and Stable Ischemic Heart Disease: The BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Trial.
Khan AA; Chung MJ; Novak E; Brown DL
J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28903941
[TBL] [Abstract][Full Text] [Related]
5. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.
Ueki K; Sasako T; Okazaki Y; Kato M; Okahata S; Katsuyama H; Haraguchi M; Morita A; Ohashi K; Hara K; Morise A; Izumi K; Ishizuka N; Ohashi Y; Noda M; Kadowaki T;
Lancet Diabetes Endocrinol; 2017 Dec; 5(12):951-964. PubMed ID: 29079252
[TBL] [Abstract][Full Text] [Related]
6. Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Brooks MM; Chaitman BR; Nesto RW; Hardison RM; Feit F; Gersh BJ; Krone RJ; Sako EY; Rogers WJ; Garber AJ; King SB; Davidson CJ; Ikeno F; Frye RL;
Circulation; 2012 Oct; 126(17):2115-24. PubMed ID: 23008442
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Bach RG; Brooks MM; Lombardero M; Genuth S; Donner TW; Garber A; Kennedy L; Monrad ES; Pop-Busui R; Kelsey SF; Frye RL;
Circulation; 2013 Aug; 128(8):785-94. PubMed ID: 23857320
[TBL] [Abstract][Full Text] [Related]
8. Impact of completeness of revascularization on long-term cardiovascular outcomes in patients with type 2 diabetes mellitus: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D).
Schwartz L; Bertolet M; Feit F; Fuentes F; Sako EY; Toosi MS; Davidson CJ; Ikeno F; King SB
Circ Cardiovasc Interv; 2012 Apr; 5(2):166-73. PubMed ID: 22496082
[TBL] [Abstract][Full Text] [Related]
9. The Bypass Angioplasty Revascularization in Type 1 and Type 2 Diabetes Study: 5-year follow-up of revascularization with percutaneous coronary intervention versus coronary artery bypass grafting in diabetic patients with multivessel disease.
Kapur A; Bartolini D; Finlay MC; Qureshi AC; Flather M; Strange JW; Hall RJ
J Cardiovasc Med (Hagerstown); 2010 Jan; 11(1):26-33. PubMed ID: 19797974
[TBL] [Abstract][Full Text] [Related]
10. Effect of prompt revascularization on outcomes in diabetic patients with stable ischemic heart disease and previous myocardial infarction in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Chung MJ; Novak E; Brown DL
Coron Artery Dis; 2017 Jun; 28(4):301-306. PubMed ID: 28346285
[TBL] [Abstract][Full Text] [Related]
11. Risk factor control for coronary artery disease secondary prevention in large randomized trials.
Farkouh ME; Boden WE; Bittner V; Muratov V; Hartigan P; Ogdie M; Bertolet M; Mathewkutty S; Teo K; Maron DJ; Sethi SS; Domanski M; Frye RL; Fuster V
J Am Coll Cardiol; 2013 Apr; 61(15):1607-15. PubMed ID: 23500281
[TBL] [Abstract][Full Text] [Related]
12. Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D).
Schwartz L; Kip KE; Alderman E; Lu J; Bates ER; Srinivas V; Bach RG; Mighton LD; Feit F; King S; Frye RL;
Am J Cardiol; 2009 Mar; 103(5):632-8. PubMed ID: 19231325
[TBL] [Abstract][Full Text] [Related]
13. Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes.
Everett BM; Brooks MM; Vlachos HE; Chaitman BR; Frye RL; Bhatt DL;
N Engl J Med; 2015 Aug; 373(7):610-20. PubMed ID: 26267622
[TBL] [Abstract][Full Text] [Related]
14. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group
Am Heart J; 2008 Sep; 156(3):528-536, 536.e1-5. PubMed ID: 18760137
[TBL] [Abstract][Full Text] [Related]
15. Association Between Triglycerides and Residual Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease (From the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] Trial).
Nelson AJ; Navar AM; Mulder H; Wojdyla D; Philip S; Granowitz C; Peterson ED; Pagidipati NJ
Am J Cardiol; 2020 Oct; 132():36-43. PubMed ID: 32773223
[TBL] [Abstract][Full Text] [Related]
16. On-pump versus off-pump coronary artery bypass graft surgery among patients with type 2 diabetes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.
Singh A; Schaff HV; Mori Brooks M; Hlatky MA; Wisniewski SR; Frye RL; Sako EY;
Eur J Cardiothorac Surg; 2016 Feb; 49(2):406-16. PubMed ID: 25968885
[TBL] [Abstract][Full Text] [Related]
17. Race/ethnic disparities in risk factor control and survival in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial.
Beohar N; Sansing VV; Davis AM; Srinivas VS; Helmy T; Althouse AD; Thomas SB; Brooks MM;
Am J Cardiol; 2013 Nov; 112(9):1298-305. PubMed ID: 23910429
[TBL] [Abstract][Full Text] [Related]
18. Insulin provision therapy and mortality in older adults with diabetes mellitus and stable ischemic heart disease: Insights from BARI-2D trial.
Damluji AA; Cohen ER; Moscucci M; Myerburg RJ; Cohen MG; Brooks MM; Rich MW; Forman DE
Int J Cardiol; 2017 Aug; 241():35-40. PubMed ID: 28314486
[TBL] [Abstract][Full Text] [Related]
19. The long-term risk of smoking in diabetic patients with stable ischemic heart disease treated with intensive medical therapy and lifestyle modification.
Khan AA; Chung MJ; Novak E; Mori Brooks M; Brown DL
Eur J Prev Cardiol; 2017 Sep; 24(14):1506-1514. PubMed ID: 28517955
[TBL] [Abstract][Full Text] [Related]
20. Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease.
Dagenais GR; Lu J; Faxon DP; Kent K; Lago RM; Lezama C; Hueb W; Weiss M; Slater J; Frye RL;
Circulation; 2011 Apr; 123(14):1492-500. PubMed ID: 21444887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
